|
1
|
No authors: listed: T he World Health
Organization classification of malignant lymphomas in Japan:
Incidence of recently recognized entities. Histopathology. Pathol
Int. 50:696–702. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Aoki R, Karube K, Sugita Y, Nomura Y,
Shimizu K, Kimura Y, Hashikawa K, Suefuji N and Kikuchi M:
Distribution of malignant lymphoma in Japan, Analysis of 2260
cases, 2001-2006. Pathol Int. 58:174–182. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ogura M, Ishida T, Hatake K, Taniwaki M,
Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T and Uike N:
Multicenter phase II study of mogamulizumab (KW-0761), a
defucosylated anti-cc chemokine receptor 4 antibody, in patients
with relapsed peripheral T-cell lymphoma and cutaneous T-cell
lymphoma. J Clin Oncol. 32:1157–1163. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Swerdlow SH, Campo E, Harris NL, et al:
WHO Classification of Tumours of Haematolopoietic and Lymphoid
Tissues (4th). Lyon: IARC. 2008.
|
|
5
|
Imai T, Nagira M, Takagi S, Kakizaki M,
Nishimura M, Wang J, Gray PW, Matsushima K and Yoshie O: Selective
recruitment of CCR4-bearing Th2 cells toward antigen-presenting
cells by the CC chemokines thymus and activation-regulated
chemokine and macrophage-derived chemokine. Int Immunol. 11:81–88.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Niwa R, Shoji-Hosaka E, Sakurada M,
Shinkawa T, Uchida K, Nakamura K, Matsushima K and Ueda R:
Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with
enhanced antibody-dependent cellular cytotoxicity shows potent
therapeutic activity to T-cell leukemia and lymphoma. Cancer Res.
64:2127–2133. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ishii T, Ishida T, Utsunomiya A, Inagaki
A, Yano H, Komatsu H, Iida S, Imada K, Uchiyama T, Akinaga S, et
al: Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761
as a novel immunotherapeutic agent for adult T-cell
leukemia/lymphoma. Clin Cancer Res. 16:1520–1531. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ohshima K, Karube K, Kawano R, Tsuchiya T,
Suefuji H, Yamaguchi T, Suzumiya J and Kikuchii M: Classification
of distinct subtypes of peripheral T-cell lymphoma unspecified,
identified by chemokine and chemokine receptor expression, Analysis
of prognosis. Int J Oncol. 25:605–613. 2004.PubMed/NCBI
|
|
9
|
Nakagawa M, Nakagawa-Oshiro A, Karnan S,
Tagawa H, Utsunomiya A, Nakamura S, Takeuchi I, Ohshima K and Seto
M: Array comparative genomic hybridization analysis of PTCL-U
reveals a distinct subgroup with genetic alterations similar to
lymphoma-type adult T-cell leukemia/lymphoma. Clin Cancer Res.
15:30–38. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ishida T and Ueda R: Immunopathogenesis of
lymphoma: Focus on CCR4. Cancer Sci. 102:44–50. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ishida T, Inagaki H, Utsunomiya A,
Takatsuka Y, Komatsu H, Iida S, Takeuchi G, Eimoto T, Nakamura S
and Ueda R: CXC chemokine receptor 3 and CC chemokine receptor 4
expression in T-cell and NK-cell lymphomas with special reference
to clinicopathological significance for peripheral T-cell lymphoma,
unspecified. Clin Cancer Res. 10:5494–5500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yamamoto K, Utsunomiya A, Tobinai K,
Tsukasaki K, Uike N, Uozumi K, Yamaguchi K, Yamada Y, Hanada S,
Tamura K, et al: Phase I study of KW-0761, a defucosylated
humanized anti-CCR4 antibody, in relapsed patients with adult
T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin
Oncol. 28:1591–1598. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Duvic M, Pinter-Brown L, Foss FM, Sokol L,
Jorgensen JL, et al: Phase 1/2 study of mogamulizumab, a
defucosylated anti-CCR4 antibody, in previously treated patients
with cutaneous T-cell lymphoma. Blood. 125:1883–1889. 2015.
View Article : Google Scholar : PubMed/NCBI
|
